As if here weren't enough things for investors to worry about, a new fear is being talked about on Wall Street. Although corporate earnings are beating expectations, financial commentators are focused on the latest weakness in the healthcare sector. With the stocks of many biotech and pharmaceutical companies in decline, many believe this is the start of a broader decline in the equity market. In today's report, however, I'll dispute this view and make the case that there is still too much fear and short interest buildup to justify the bleak stock market outlook of